The Danger of Smoking and E-cigarettes in Brazil

Sep.02.2022
The Danger of Smoking and E-cigarettes in Brazil
Smoking is the primary cause of lung cancer in Brazil's Mato Grosso state, with e-cigarettes becoming a popular and dangerous alternative.

In the state of Mato Grosso do Sul in Brazil, there are 15.6 cases of tracheal, bronchial, and lung cancer per 100,000 males and 7.9 cases per 100,000 females, with similar ratios. According to data from the US National Cancer Institute (INCA), these types of tumors are primarily caused by smoking.


Smoking is the second leading cause of cancer in men, with only prostate cancer having a higher incidence rate. In women, it is the third leading cause, following breast and cervical cancer.


Giovanna Figaredo, a pulmonologist who works at the St. Matthew's Hospital in Cubatão, believes that in addition to traditional smoking methods such as cigarettes, cigars, and pipes, electronic cigarettes are becoming a popular and harmful trend, especially among young people.


Many individuals believe that electronic cigarettes are "healthier," but this is a myth. We must uncover the mysterious veil of this information in order to guide people away from consumption. Electronic cigarettes are banned in Brazil because they are unsafe. Many people are even unaware of what they are inhaling, the doctor explained.


This pulmonologist has warned that smoking increases the risk of more than 20 types of cancers, in addition to the most common ones such as lung cancer, bronchial cancer, and tracheal cancer. Furthermore, smoking also increases the risk of cardiovascular diseases such as heart disease and stroke. It can lead to pulmonary diseases like chronic obstructive pulmonary disease (COPD), emphysema, chronic bronchitis, and decreased fertility.


In regards to e-cigarettes, the long-term damage of their use is still largely unknown due to the higher consumption rates of this generation. However, there have been cases of patients with deteriorating lung conditions such as asthma. Additionally, there is EVALI (electronic cigarette or vaping product use-associated lung injury), which is an acute lung disease associated with the use of e-cigarettes," he pointed out.


Nicotine is a disease.


Doctor Giovanna Figueiredo explained that nicotine addiction is considered a disease and is classified under the International Classification of Diseases (ICD). It can lead to physical and psychological dependency.


Experts emphasize that the first step to overcoming the difficulties of quitting smoking is willpower and determination. "I usually guide people to make changes in their daily habits, such as changing the place where they usually keep their cigarettes, delaying the first cigarette of the day as much as possible, and avoiding drinks that encourage smoking, such as coffee and alcoholic beverages. After making these changes, it is important to set a date to permanently quit tobacco use.


Doctors emphasize that certain medications can assist with quitting smoking and also help control withdrawal symptoms and anxiety. They point out that seeking professional help for guidance, planning, and medication prescriptions is crucial when needed.


Statement:


This article is compiled from third-party information and is only intended for industry-related exchange and learning.


This article does not reflect the views of 2FIRSTS and 2FIRSTS cannot confirm the authenticity or accuracy of the article's content. The article's translation is only intended for industry-related communication and research purposes.


Due to limitations in the translator's ability, translated articles may not accurately reflect the original text. It is recommended to refer to the original text for accuracy.


In regards to any domestic, Hong Kong, Macao, Taiwan, or foreign affairs, 2FIRSTS maintains complete alignment with the Chinese government.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us to have it removed.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
The U.S. Department of Health and Human Services has named Bret Koplow permanent director of the FDA’s Center for Tobacco Products, ending his period as acting chief. Koplow has spent years working on tobacco regulation, law and policy inside the FDA and, while serving as acting director, pushed for faster PMTA reviews and nicotine pouch review pilots. HHS also said CTP will prioritize innovation and access to less harmful alternatives for adult smokers while continuing efforts to protect youth.
Sep.09
Imperial Brands Acquires Helwit Owner Yoik Group for SEK 515 Million, More Than Doubling Swedish Nicotine Pouch Share
Imperial Brands Acquires Helwit Owner Yoik Group for SEK 515 Million, More Than Doubling Swedish Nicotine Pouch Share
Imperial Brands has agreed to acquire 100% of Swedish modern oral nicotine company Yoik Group AB for an initial SEK515 million, equivalent to about US$53.9 million, plus a deferred payment linked to performance over the next two years. Yoik owns nicotine pouch brand Helwit, which held about 3.4% of Sweden’s modern oral nicotine market over the past 12 months. Imperial says the acquisition will more than double its existing share of the Swedish market. Helwit is also sold elsewhere in the Nordics, through European online channels and in selected UK retail outlets.
Sep.08
Ireland Raises Nicotine Product Taxes Again as Cigarettes Gain €1 and Vape Duty Is Set to Jump 40%
Ireland Raises Nicotine Product Taxes Again as Cigarettes Gain €1 and Vape Duty Is Set to Jump 40%
Ireland has increased tobacco excise under Budget 2027 and announced a further rise in its E-liquid Products Tax. From Oct. 7, the tax burden on a pack of 20 cigarettes in the most popular price category increased by €1, with pro-rata increases on other tobacco products. The government plans to raise EPT from €0.50 to €0.70 per millilitre from Jan. 1, 2027, a 40% increase applying to both nicotine-containing and nicotine-free e-liquids. The tobacco duty increase is expected to raise about €63.1 million in a full year.
Regulations
Oct.09
Product | PMJ Adds Bold Ruby to IQOS ILUMA i Lineup in Japan, Convenience-Store Rollout Starts Sept. 29
Product | PMJ Adds Bold Ruby to IQOS ILUMA i Lineup in Japan, Convenience-Store Rollout Starts Sept. 29
Philip Morris Japan (PMJ) launched Bold Ruby as a new regular color for the IQOS ILUMA i and IQOS ILUMA i ONE in Japan on September 16, 2026, priced at JPY 6,980 and JPY 3,980, respectively. Initial sales began through IQOS online and physical channels, with convenience stores and selected tobacco retailers set to follow from September 29. Bold Ruby is a regular rather than limited-edition colorway and is available for the ILUMA i and ILUMA i ONE, but not the ILUMA i PRIME. The release does not involve changes to the devices' core hardware or functions.
Sep.22
Product | KUMI SCENIC 50K Offers Nicotine and 6-Methyl Nicotine Versions as 6-MN Products Appear in Multiple U.S. State Directories, With Louisiana Listing FDA Exemption
Product | KUMI SCENIC 50K Offers Nicotine and 6-Methyl Nicotine Versions as 6-MN Products Appear in Multiple U.S. State Directories, With Louisiana Listing FDA Exemption
An October 2026 review of U.S. state vapor product directories found KUMI 6 SCENIC 50K listed in Louisiana and Nebraska. Louisiana classifies 20 related product entries as “FDA EXEMPTION.” The SCENIC platform is marketed in both conventional nicotine-salt and NoNic6 formulations, each advertised with 22mL e-liquid capacity and up to 50,000 puffs. U.S. wholesaler Midwest Goods listed both versions in August 2025 with a suggested retail price of $19.99 each. The NoNic6 version is associated with 6-methylnicotine and is also marketed by some distributors as “nicotine-free.”
product
Oct.27
From Product Innovation to Integrated Solutions: NEXTECH Expands Its Global Heated Tobacco Solutions
From Product Innovation to Integrated Solutions: NEXTECH Expands Its Global Heated Tobacco Solutions
NEXTECH launched its NEXE Pro circumferential-heating tobacco stick globally at InterTabac 2026, as the company expands from product innovation into broader heated tobacco solutions. Amid intensifying competition across global HTP markets, NEXTECH is strengthening its R&D, manufacturing and pre-launch support capabilities to serve different types of business customers.
Industry Insight
Sep.15